Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Rxi Pharmaceuticals Corp (NASDAQ:RXII)

0.62
Delayed Data
As of Jun 26
 -0.0042 / -0.67%
Today’s Change
0.51
Today|||52-Week Range
2.93
-13.25%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$13.8M

Company Description

RXi Pharmaceuticals Corp. is a biotechnology company, which engages in developing therapeutics that address unmet medical needs. Its clinical product candidate includes RXI-109, a RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Contact Information

RXi Pharmaceuticals Corp.
257 Simarano Drive
Marlborough Massachusetts 01752
P:(508) 767-3861
Investor Relations:
(508) 929-3646

Employees

Shareholders

Individual stakeholders5.93%
Other institutional1.37%
Mutual fund holders0.45%

Top Executives

Geert CauwenberghPresident, CEO, CFO & Director
Karen BulockVice President-Research
Alexey V. EliseevChief Business Officer
Gerrit DispersynCo-Chief Development Officer
Caitlin KontulisSecretary & Principal Accounting Officer